Acurx Pharmaceuticals LLC (ACXP)

Currency in USD
3.100
+0.320(+11.51%)
Closed·
3.122+0.022(+0.72%)
·
ACXP is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2.9003.180
52 wk Range
1.32621.000
Key Statistics
Prev. Close
2.78
Open
2.94
Day's Range
2.9-3.18
52 wk Range
1.326-21
Volume
115.14K
Average Vol. (3m)
3.15M
1-Year Change
-59.2105%
Book Value / Share
2.24
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ACXP Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
17.000
Upside
+448.39%
Members' Sentiments
Bearish
Bullish
ProTips
Stock generally trades with high price volatility

Acurx Pharmaceuticals LLC News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company’s lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus (MRSA), vancomycin resistant enterococcus (VRE), and drug-resistant streptococcus pneumoniae (DRSP), as well as B. anthracis. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.

Acurx Pharmaceuticals LLC Earnings Call Summary for Q4/2025

  • Cash balance surged 105.4% YoY to $7.6M; Q4 net loss improved 42.9% to $1.6M with R&D expenses down 62.5% reflecting cost management.
  • Ibezapolstat achieved 96% clinical cure rate in Phase 2 trials for C. difficile infections, demonstrating strong efficacy in key development program.
  • Company initiating new clinical trial for recurrent CDI, targeting shift from two-agent to one-agent therapy to reduce recurrence rates.
  • Stock dropped 15.17% to $5.01 despite improved financials; analysts maintain 'Strong Buy' rating with price targets ranging $4-$31.
  • CEO Luci emphasized strengthened financial position enables focus on advancing clinical programs to address urgent C. difficile treatment needs.
Last Updated: 03/13/2026, 08:58 AM
Read Full Transcript

Compare ACXP to Peers and Sector

Metrics to compare
ACXP
Peers
Sector
Relationship
P/E Ratio
−1.0x−3.4x−0.5x
PEG Ratio
−0.010.040.00
Price / Book
1.5x4.0x2.6x
Price / LTM Sales
-7.7x3.2x
Upside (Analyst Target)
259.7%72.0%47.6%
Fair Value Upside
Unlock3.0%6.1%Unlock

Analyst Ratings

3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 17.000
(+448.39% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Buy31.00+900.00%-MaintainOct 01, 2025
H.C. Wainwright
Buy31.00+900.00%8.00MaintainAug 13, 2025
H.C. Wainwright
Buy8.00+158.06%-New CoverageMay 15, 2025

Earnings

Latest Release
Mar 12, 2026
EPS / Forecast
-0.73 / -0.13
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

ACXP Income Statement

People Also Watch

2.000
TURB
-2.44%
0.540
SGN
-22.73%
1.28
TMDE
-3.76%
2.900
MOBX
+10.27%

FAQ

What Is the Acurx Pharmaceuticals LLC (ACXP) Stock Price Today?

The Acurx Pharmaceuticals LLC stock price today is 3.100 USD.

What Stock Exchange Does Acurx Pharmaceuticals LLC Trade On?

Acurx Pharmaceuticals LLC is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Acurx Pharmaceuticals LLC?

The stock symbol for Acurx Pharmaceuticals LLC is "ACXP."

What Is the Acurx Pharmaceuticals LLC Market Cap?

As of today, Acurx Pharmaceuticals LLC market cap is 9.020M USD.

What Is Acurx Pharmaceuticals LLC's Earnings Per Share (TTM)?

The Acurx Pharmaceuticals LLC EPS (TTM) is -5.315.

When Is the Next Acurx Pharmaceuticals LLC Earnings Date?

Acurx Pharmaceuticals LLC will release its next earnings report on Nov 18, 2025.

From a Technical Analysis Perspective, Is ACXP a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Acurx Pharmaceuticals LLC Stock Split?

Acurx Pharmaceuticals LLC has split 1 times.

How Many Employees Does Acurx Pharmaceuticals LLC Have?

Acurx Pharmaceuticals LLC has 4 employees.

What is the current trading status of Acurx Pharmaceuticals LLC (ACXP)?

As of Apr 15, 2026, Acurx Pharmaceuticals LLC (ACXP) is trading at a price of 3.100 USD, with a previous close of 2.780 USD. The stock has fluctuated within a day range of 2.900 USD to 3.180 USD, while its 52-week range spans from 1.326 USD to 21.000 USD.

What Is Acurx Pharmaceuticals LLC (ACXP) Price Target According to Analysts?

The average 12-month price target for Acurx Pharmaceuticals LLC is 17.000 USD, with a high estimate of 31 USD and a low estimate of 10 USD. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +448.39% Upside potential.

What Is the ACXP Premarket Price?

ACXP's last pre-market stock price is 2.970 USD. The pre-market share volume is 10,180.000, and the stock has decreased by 0.190, or 6.830%.

What Is the ACXP After Hours Price?

ACXP's last after hours stock price is 3.122 USD, the stock has decreased by 0.022, or 0.720%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.